Altimmune earnings release, August 12, 2026

Altimmune, Inc. (ALT) · Form 8-K, Item 2.02 · Filed · SEC filing

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

​

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

​

GAITHERSBURG, MD – August 12, 2026 – Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.

“We have achieved several important milestones as we continue to successfully execute our strategy, including the initiation of the PERFORMA Phase 3 MASH trial and positive topline data from the RECLAIM Phase 2 AUD trial. The team remains focused on advancing our differentiated pemvidutide franchise in both MASH and AUD, each an area of unmet need with substantial future sales potential,” said Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune. “We are also pleased to announce completion of enrollment in the RESTORE Phase 2 ALD trial. Our momentum positions Altimmune to deliver on our goals of bringing pemvidutide to patients with serious liver diseases and creating value for shareholders.”

​

Key Highlights and Anticipated Milestones

​

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

​

Alcohol Use Disorder (AUD)

​

Alcohol-associated Liver Disease (ALD)

​

Corporate Updates

​

​

​

​

Financial Results for the Three Months Ended June 30, 2026

​

Conference Call Information:

​

Following the conclusion of the call, the webcast will be available for replay on the IR page of the Company’s website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

About Pemvidutide

Pemvidutide is an investigational novel peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity that has an effect on reducing liver fat, inflammation, and fibrosis, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss and are involved in pathways related to craving and reward.

​

The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, the Company announced topline 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH was initiated. In July 2026, the Company announced positive topline results from the RECLAIM Phase 2 trial in AUD. In July 2026, the Company completed enrollment of the RESTORE Phase 2 trial in ALD.

​

​

​

​

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

​

Follow @Altimmune, Inc. on

LinkedIn

Follow @AltimmuneInc on

X

​

​

​

Financial statements

Income Statement

Three Months Ended — (In thousands, except share and per-share amounts)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Revenues$—5$—10
Operating expenses:Research and development18,65517,23634,84733,063
Operating expenses:General and administrative7,5745,69115,62611,684
Operating expenses:Total operating expenses26,22922,92750,47344,747
Operating expenses:Loss from operations-26,229-22,922-50,473-44,737
Other income (expense):Interest expense-1,097-264-2,165-265
Other income (expense):Interest income4,5261,1327,4272,677
Other income (expense):Other income (expense), net-25-92-177-77
Other income (expense):Total other income (expense), net3,4047765,0852,335
Other income (expense):Net loss before income taxes-22,825-22,146-45,388-42,402
Other income (expense):Income tax expense (benefit)-681
Other income (expense):Net loss-22,825-22,146-45,388-41,721
Other income (expense):Other comprehensive income — unrealized loss on investments-814-36-1,110-66
Other income (expense):Comprehensive loss-23,639-22,182-46,498-41,787
Other income (expense):Net loss per share, basic and diluted-0.12-0.27-0.29-0.53
Other income (expense):Weighted-average common shares outstanding, basic and diluted185,443,73681,477,548155,121,23578,529,028

Balance Sheet

December 31, — (In thousands, except share and per-share amounts)

June 30, – 2026 – (Unaudited)December 31, – 2025
Current assets:Cash and cash equivalents63,00843,760
Current assets:Restricted cash4242
Current assets:Total cash, cash equivalents and restricted cash63,05043,802
Current assets:Short-term investments263,273229,696
Current assets:Accounts and other receivables3,3411,219
Current assets:Income tax and R&D incentive receivables518
Current assets:Prepaid expenses and other current assets5,1512,957
Current assets:Total current assets334,815278,192
Current assets:Long-term investments192,247
Current assets:Property and equipment, net60312
Current assets:Other assets901,425
Current assets:Total assets527,212279,929
Current liabilities:Accounts payable1,2722,717
Current liabilities:Accrued expenses and other current liabilities11,22912,280
Current liabilities:Total current liabilities12,50114,997
Current liabilities:Term loan, noncurrent34,74234,287
Current liabilities:Other noncurrent liabilities5,7615,753
Current liabilities:Total liabilities53,00455,037
Stockholders’ equity:Common stock, $0.0001 par value; 400,000,000 and 200,000,000 shares authorized; 194,474,154 and 110,882,735 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1911
Stockholders’ equity:Additional paid-in capital1,175,098879,292
Stockholders’ equity:Accumulated deficit-694,871-649,483
Stockholders’ equity:Accumulated other comprehensive loss, net-6,038-4,928
Stockholders’ equity:Total stockholders’ equity474,208224,892
Stockholders’ equity:Total liabilities and stockholders’ equity527,212279,929
Full release

Forward-Looking Statements

Any statements made in this press release related to the development or commercialization of pemvidutide, an investigational product candidate, and other business, regulatory and financial matters including without limitation, clinical trial study design, status, correspondence, results and data, including the ongoing PERFORMA and RESTORE trials, the timing of key milestones for the Company’s clinical programs, future plans or expectations for pemvidutide for the treatment of MASH, AUD and ALD, the potential benefits of Fast Track and Breakthrough Therapy Designations, including potential regulatory timeline and approval benefits, the Company’s financial position, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, financial results, and the impact of the changes to our leadership and governance structure, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K, quarterly report on Form 10-Q and the Company’s other filings with the SEC, which are available at www.sec.gov.

Investor Contact:

​

Media Contact:

​

​

​

​

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.